<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04471415</url>
  </required_header>
  <id_info>
    <org_study_id>DRA-104-001</org_study_id>
    <secondary_id>2020-002770-27</secondary_id>
    <nct_id>NCT04471415</nct_id>
  </id_info>
  <brief_title>First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors.</brief_title>
  <official_title>Phase 1 and Phase 2a, First-in-human Study of DRP-104 (Sirpiglenastat), a Glutamine Antagonist, in Adult Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dracen Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dracen Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety, tolerability, pharmacokinetics,&#xD;
      pharmaco-dynamics and preliminary anti-tumor activity of DRP-104 (sirpiglenastat)&#xD;
      administered via intravenous infusion or via subcutaneous injection as a single agent and in&#xD;
      combination with atezolizumab in patients with advanced solid tumors and to assess&#xD;
      preliminary safety and efficacy of which route of administration (intravenous or&#xD;
      subcutaneous) will be selected for further development for the other two expansions of&#xD;
      patients, advanced non-small cell lung cancer (NSCLC) with defined genetic mutations, and&#xD;
      advanced squamous cell carcinoma of the head and neck (SCCHN).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted in 4 Parts:&#xD;
&#xD;
      Part 1: Phase 1 single-agent dose escalation of DRP-104 (sirpiglenastat) in patients with&#xD;
      advanced solid tumors to define the MTD (up to approximately 50 patients for each intravenous&#xD;
      and subcutaneous cohort)&#xD;
&#xD;
      Part 2, Once the MTD of DRP-104 for the IV and subQ route of administration will be&#xD;
      determined in Part 1, Part 2 will include 2 specific cohorts: Cohort 2 and 3 with one only&#xD;
      selected formulation. Once the MTD of DRP-104 has been declared for either the IV or suQ&#xD;
      cohort, Cohort 1 of Part 2 will separately expand for each cohort. -Cohort 1: Phase 1&#xD;
      single-agent safety expansion at the of DRP-104 in patients with advanced solid tumors (N=&#xD;
      minimum of 14 and up to 20 patients for each intravenous and subcutaneous cohorts); The&#xD;
      Sponsor will determine at completion of Phase 1 which route of administration will be further&#xD;
      developed and continued for all subsequent Cohorts 2 and 3 and Parts 3 and Part 4 in&#xD;
      combination with atezolizumab.&#xD;
&#xD;
        -  Cohort 2: Phase 2a expansion at the of DRP-104 in patients with locally advanced or&#xD;
           metastatic NSCLC whose tumors contain a KEAP1 mutation, NFE2L2 mutation and/or STK11&#xD;
           mutation (N=55 patients)&#xD;
&#xD;
        -  Cohort 3: Phase 2a expansion at the MTD of DRP-104 in recurrent, unresectable or&#xD;
           metastatic SCCHN (N=15-25 patients).&#xD;
&#xD;
      Part 3: Phase 1 combination dose escalation of DRP-104 (sirpiglenastat) (with either IV or&#xD;
      subcutaneous formulation selected) and atezolizumab in patients with advanced solid tumors&#xD;
      previously treated with an anti-PD-1, anti PD-L1, and/or anti-CTLA-4 antibody, starting one&#xD;
      dose level below the MTD of single-agent DRP-104 and in combination with atezolizumab (up to&#xD;
      approximately N=12 patients).&#xD;
&#xD;
      Part 4: Phase 1 combination safety expansion at the MTD of DRP-104 (with either IV or&#xD;
      subcutaneous formulation selected)with atezolizumab in a similar patient population as the&#xD;
      dose-escalation (N=14 patients).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose Escalation cohort, followed by Dose Expansion cohort, followed by NSCLC, SCCHN and combination with atezolizumab cohorts.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD</measure>
    <time_frame>anticipated 1 year</time_frame>
    <description>Safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>anticipated 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of DRP-104</measure>
    <time_frame>anticipated 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>anticipated 2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>anticipated 2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>anticipated 2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>anticipated 2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>anticipated 2 year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">246</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Non-Small Cell Lung Cancer Recurrent</condition>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <condition>Non Small Cell Lung Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Part 1a &amp; Part 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-agent dose escalation of DRP-104 to define the MTD (up to approximately 50 patients) starting at Dose Level 1 of 3.3 mg/m2 via intravenous injection&#xD;
Single-agent dose escalation of DRP-104 to define the MTD (up to approximately 50 patients) starting at Dose Level 1 at 10 mg via subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1a: Phase 1 single-agent safety expansion at the of intravenous DRP-104 in patients with advanced solid tumors (N=14 up to 20 patients);&#xD;
Cohort 1b: Phase 1 single-agent safety expansion at the of subcutaneous DRP-104 in patients with advanced solid tumors (N=14 up to 20 patients);&#xD;
Cohort 2: Phase 2a expansion at the of DRP-104 at the recommended selected route of administration (intravenous or subcutaneous) in patients with locally advanced or metastatic NSCLC whose tumors contain a KEAP1 mutation, NFE2L2 mutation and/or STK11 mutation (N=55 patients)&#xD;
Cohort 3: Phase 2a expansion at the MTD of DRP-104 at the recommended selected route of administration (intravenous or subcutaneous) in recurrent, unresectable or metastatic SCCHN (N=15-25 patients).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of DRP-104 at 1 dose level below declared MTD at the selected recommended route of administration (intravenous or subcutaneous) in combination with atezolizumab in patients with advanced solid tumors previously treated with an anti-PD-1, anti PD-L1, and/or anti-CTLA-4 antibody (up to approximately (N=12 patients).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose expansion at the MTD of DRP-104 at the selected recommended route of administration (intravenous or subcutaneous) with atezolizumab (N=14 patients).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DRP-104</intervention_name>
    <description>DRP-104 administered intravenously over 1 hour, three times per week (TIW) (Monday, Wednesday, Friday) for 2 consecutive weeks, one week off&#xD;
DRP-104 administered subcutaneously twice weekly (Monday/Thursday or Tuesday/Friday) every week</description>
    <arm_group_label>Part 1a &amp; Part 1b</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_label>Part 3</arm_group_label>
    <arm_group_label>Part 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>atezolizumab</intervention_name>
    <description>atezolizumab administered intravenously over 1 hour at 1200 mg once every 3 weeks.</description>
    <arm_group_label>Part 3</arm_group_label>
    <arm_group_label>Part 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of advanced or recurrent, histologically or cytologically confirmed,&#xD;
             measurable by RECIST 1.1 metastatic or unresectable solid tumor&#xD;
&#xD;
          -  Patient must have progressed on, be intolerant of, decline, or be ineligible for, all&#xD;
             available standard of care therapies&#xD;
&#xD;
          -  Part 2: locally advanced or metastatic NSCLC with KEAP1, NFE2L2 and/or STK11 mutation&#xD;
             ; Patients must have received at least a platinum doublet chemotherapy and an&#xD;
             anti-PD-(L)1 antibody; Received up to 3 lines of systemic anticancer therapy in the&#xD;
             recurrent or metastatic setting&#xD;
&#xD;
          -  Part 2: Recurrent, unresectable or metastatic squamous cell carcinoma of the head and&#xD;
             neck (SCCHN) (oropharynx, oral cavity, hypopharynx or larynx); Patient must have&#xD;
             received platinum containing chemotherapy and antiPD-(L)1 antibody in recurrent or&#xD;
             metastatic setting&#xD;
&#xD;
          -  Part 3 and 4 - DRP-104 + atezolizumab Prior exposure to any checkpoint inhibitor&#xD;
             (anti-PD-1, anti-PD-L1, anti-PDL2, and/or anti-CTLA-4 antibody)&#xD;
&#xD;
          -  ECOG performance 0 or 1&#xD;
&#xD;
          -  Patient must consent to allow acquisition of existing FFPE tumor tissue; If&#xD;
             unavailable, patient must consent to new pre-treatment tumor biopsy&#xD;
&#xD;
          -  All SCCHN patient, all NSCLC patients and all patients treated with combination of&#xD;
             DRP-104 and atezolizumab will be required to undergo pre-treatment and post-treatment&#xD;
             core or excisional biopsies.&#xD;
&#xD;
          -  Pre-treatment and post-treatment core or excisional biopsies are optional for all&#xD;
             remaining patients&#xD;
&#xD;
          -  Adequate baseline organ function as defined by: Absolute neutrophil count ≥ 1.5 ×&#xD;
             109/L (1500/µL); Hemoglobin ≥ 9 g/dL ;Platelets ≥ 75 × 109/L (75,000/µL); Hepatic&#xD;
             Total bilirubin ≤1.5 × upper limit of normal (ULN): PT/INR and PTT ≤1.5 × ULN, unless&#xD;
             treated with warfarin; AST(SGOT)/ALT(SGPT) ≤3 × ULN or ≤ 5 × ULN for patients with&#xD;
             liver metastases; Creatinine clearance ≥ 60 ml/min/1.73m2 measured or calculated&#xD;
&#xD;
          -  Cardiac QTc (Fridericia) &lt;470 ms&#xD;
&#xD;
          -  Women of child-bearing potential and men who are sexually active must agree to use one&#xD;
             highly effective method of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with primary central nervous system tumors and hepatocellular carcinoma&#xD;
&#xD;
          -  Patients with progressive or symptomatic brain metastases&#xD;
&#xD;
          -  Leptomeningeal disease&#xD;
&#xD;
          -  Spinal cord compression not definitively treated with surgery and/or radiation&#xD;
&#xD;
          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent&#xD;
             drainage&#xD;
&#xD;
          -  Prior glutaminase inhibitor use&#xD;
&#xD;
          -  Prior systemic anticancer treatment (i.e. chemotherapy, biologic therapy, monoclonal&#xD;
             antibodies, investigational agents) within 21 days or 5 half-lives, whichever is&#xD;
             shorter&#xD;
&#xD;
          -  Anti-androgen therapies for prostate cancer, such as bicalutamide, within 4 weeks&#xD;
             prior to enrollment&#xD;
&#xD;
          -  Prior small port palliative radiotherapy within 14 days of start of Cycle 1&#xD;
&#xD;
          -  Any major surgery within 21 days from start of Cycle 1&#xD;
&#xD;
          -  Secondary malignancy that is progressing or has required active treatment within the&#xD;
             past 3 years, except basal cell carcinoma of the skin, squamous cell carcinoma of the&#xD;
             skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have&#xD;
             undergone potentially curative therapy&#xD;
&#xD;
          -  Has a known history of HIV, or HBV&#xD;
&#xD;
          -  Gastrointestinal (GI) function impairment or GI disease&#xD;
&#xD;
          -  Significant, uncontrolled heart disease and/or cardiac repolarization abnormality&#xD;
&#xD;
          -  Exclusion specific to only Part 3 and 4 (DRP-104 combined with atezolizumab): History&#xD;
             of severe allergic, anaphylactic to chimeric or humanized antibodies or fusion&#xD;
             proteins; Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese&#xD;
             hamster ovary cells; Prior anti-PD-1, anti-PD-L1 and/or anti CTLA4- agent, patient&#xD;
             must not have had a serious (&gt; Grade 3) immune-related AE requiring treatment; History&#xD;
             of autoimmune disease except hypothyroidism on thyroid replacement hormone therapy;&#xD;
             History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis&#xD;
             obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active&#xD;
             pneumonitis; Patients with underlying condition requiring systemic corticosteroids&#xD;
             (&gt;10 mg daily prednisone equivalents) or other immunosuppressive medications or other&#xD;
             systemic immunosuppressant medications may be enrolled in the study after approval by&#xD;
             the Medical Monitor; Evidence or history of active or latent tuberculosis infection;&#xD;
             Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunil Sharma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HonorHealth Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margaret Dugan, MD</last_name>
    <phone>973-489-7163</phone>
    <email>mdugan@dracenpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francois Lafleur, MPH</last_name>
    <phone>917-330-3971</phone>
    <email>FLafleur@dracenpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HonorHealth</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sunil Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aaron Lisberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Kimmel Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tanguy Siewert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vamsidhar Velcheti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Health Systems</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029-6574</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Deborah Doroshow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shetal Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Melissa Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Gibson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum fur Integrieerte Onkologie</name>
      <address>
        <city>Cologne</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MD</last_name>
    </contact>
    <investigator>
      <last_name>Matthias Scheffler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jurgen Wolfe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.dracenpharma.com/</url>
    <description>Company website with scientific background on DRP-104</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 25, 2020</study_first_submitted>
  <study_first_submitted_qc>July 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2020</study_first_posted>
  <last_update_submitted>June 20, 2021</last_update_submitted>
  <last_update_submitted_qc>June 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

